Abstract
Tumor lysis syndrome (TLS) is a rare but potentially life-threatening complication of neoplasms, preferentially hematological malignancies. Well known since at least ninety years ago, this condition can be misdiagnosed and incorrectly managed due to rapid onset of symptoms, sometimes overlapping with cancer-derived clinical conditions. Our purpose is to discuss some old and new issues of this syndrome. Predisposing factors as type of malignancy, chemotherapy regimen and age are promptly available and useful tools for inducing TLS suspicion. Management of clinical syndrome requires hydration, fluid balance, electrolytes and hyperuricemia correction, and ultimately dialysis when acute kidney injury is worsening.
| Lingua originale | Inglese |
|---|---|
| pagine (da-a) | 1-12 |
| Numero di pagine | 12 |
| Rivista | Expert Review of Hematology |
| DOI | |
| Stato di pubblicazione | Pubblicato - 2016 |
OSS delle Nazioni Unite
Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile
-
SDG 3 Salute e benessere
Keywords
- Tumor lysis syndrome
- allopurinol
- drug induced
- rasburicase
Fingerprint
Entra nei temi di ricerca di 'Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency'. Insieme formano una fingerprint unica.Cita questo
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver